Please assess the completion status of the following clinical trial:

Trial Title: Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven classical Hodgkin lymphoma~* First diagnosis, no previous treatment, age: 18-60 years~* Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease~Exclusion Criteria:~* Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)~* Previous malignancy~* Prior chemotherapy or radiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BrECAPP (Type: ACTIVE_COMPARATOR): modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
- BrECADD (Type: ACTIVE_COMPARATOR): modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).